These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 19923989

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
    Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G, HPV-010 Study Group.
    Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
    [Abstract] [Full Text] [Related]

  • 3. Currently approved prophylactic HPV vaccines.
    Harper DM.
    Expert Rev Vaccines; 2009 Dec; 8(12):1663-79. PubMed ID: 19943762
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
    Godi A, Panwar K, Haque M, Cocuzza CE, Andrews N, Southern J, Turner P, Miller E, Beddows S.
    Vaccine; 2019 Apr 24; 37(18):2455-2462. PubMed ID: 30926298
    [Abstract] [Full Text] [Related]

  • 12. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.
    Schiller JT, Castellsagué X, Villa LL, Hildesheim A.
    Vaccine; 2008 Aug 19; 26 Suppl 10(Suppl 10):K53-61. PubMed ID: 18847557
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
    FUTURE I/II Study GroupDepatment of Laboratory Medicine, Lund University, Malmö, Sweden. joakim.dillner@med.lu.se, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R.
    BMJ; 2010 Jul 20; 341():c3493. PubMed ID: 20647284
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years.
    Yoshikawa H, Ebihara K, Tanaka Y, Noda K.
    Cancer Sci; 2013 Apr 20; 104(4):465-72. PubMed ID: 23331518
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Human papillomavirus vaccines.
    Schmiedeskamp MR, Kockler DR.
    Ann Pharmacother; 2006 Apr 20; 40(7-8):1344-52. PubMed ID: 16849621
    [Abstract] [Full Text] [Related]

  • 19. The impact of preventive HPV vaccination.
    Roden R, Monie A, Wu TC.
    Discov Med; 2006 Oct 20; 6(35):175-81. PubMed ID: 17234138
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.